Trial Profile
Clinical Efficacy Of Subcutaneous and Sublingual Immunotherapy In Asthma and Rhinitis Children Sensitized To House Dust Mites
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary) ; House dust mite allergy immunotherapy-ALK Abello
- Indications Allergic asthma; Allergic rhinitis
- Focus Therapeutic Use
- 16 Dec 2015 New trial record